John A. Bartholdson net worth and biography

John Bartholdson Biography and Net Worth

Director of Bioventus

John Bartholdson is the co-founder and partner of Juniper Investment Company, LLC, a private investment management firm investing in publicly traded companies and private companies through concentrated ownership positions. His significant governance, finance, and transactional experience with multiple public and private companies make him active on several other boards and committees.

Mr. Bartholdson presently serves as the Chairman of the board of directors of Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets. Since 2019, he has been a member of the board of directors of Lincoln Educational Services Corporation, a public company and a leading provider of career education and training services, and presently serves on its Compensation, Audit and Nominating and Corporate Governance Committees. He also served as a member of the board of directors of Obagi Medical Products, Inc., a public specialty pharmaceutical company, until its acquisition by Valeant Pharmaceuticals in 2013.

Mr. Bartholdson was a Partner of Stonington Partners. Prior to that, he was an analyst at Merrill Lynch Capital Partners. He received his B.A. from Duke University and his M.B.A. from Stanford Graduate School of Business.

What is John A. Bartholdson's net worth?: The estimated net worth of John A. Bartholdson is at least $59.60 million as of August 16th, 2024. Bartholdson owns 6,913,857 shares of Bioventus stock worth more than $59,597,447 as of March 13th. This net worth approximation does not reflect any other investments that Bartholdson may own. Learn More about John A. Bartholdson's net worth.
How do I contact John A. Bartholdson?: The corporate mailing address for Bartholdson and other Bioventus executives is 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, NC, 27703. Bioventus can also be reached via phone at (919) 474-6700 and via email at [email protected]. Learn More on John A. Bartholdson's contact information.
Has John A. Bartholdson been buying or selling shares of Bioventus?: John A. Bartholdson has not been actively trading shares of Bioventus in the last ninety days. Most recently, on Monday, August 19th, John A. Bartholdson bought 25,500 shares of Bioventus stock. The stock was acquired at an average cost of $8.55 per share, with a total value of $218,025.00. Following the completion of the transaction, the director now directly owns 6,939,357 shares of the company's stock, valued at $59,331,502.35. Learn More on John A. Bartholdson's trading history.
Who are Bioventus' active insiders?: Bioventus' insider roster includes John Bartholdson (Director), Katrina Church (SVP), Robert Claypoole (CEO), Anthony D'Adamio (SVP), P III (CEO), Michelle Mcmurry-Heath (Director), Guy Nohra (Director), Kenneth Reali (CEO), Mark Singleton (Sr. VP), and Mark Singleton (CFO). Learn More on Bioventus' active insiders.
Are insiders buying or selling shares of Bioventus?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 53,031 shares worth more than $427,812.14. The most recent insider tranaction occured on March, 11th when Director Michelle Mcmurry-Heath sold 12,000 shares worth more than $105,480.00. Insiders at Bioventus own 33.0% of the company. Learn More about insider trades at Bioventus.
Information on this page was last updated on 3/11/2026.

John A. Bartholdson Insider Trading History at Bioventus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/19/2024	Buy	25,500	$8.55	$218,025.00	6,939,357
8/16/2024	Buy	80,000	$8.55	$684,000.00	6,913,857
8/10/2023	Buy	111,848	$4.47	$499,960.56	6,768,835
6/14/2023	Buy	181,946	$3.24	$589,505.04	6,546,807
6/12/2023	Buy	395,401	$2.92	$1,154,570.92	6,304,537
5/22/2023	Buy	178,998	$2.08	$372,315.84	5,909,136
5/19/2023	Buy	1,136,675	$1.94	$2,205,149.50	5,730,138

John A. Bartholdson Buying and Selling Activity at Bioventus

Bioventus Company Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Today's Range

Now: $8.62

$8.56

$8.79

50 Day Range

MA: $8.25

$7.57

$9.10

2 Week Range

Now: $8.62

$5.81

$10.13

Volume

286,351 shs

Average Volume

334,578 shs

Market Capitalization

$716.75 million

P/E Ratio

26.12

Dividend Yield

N/A

Beta

0.78